These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 33417139)

  • 1. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
    Jiang K; Xu Y; Wang D; Chen F; Tu Z; Qian J; Xu S; Xu Y; Hwa J; Li J; Shang H; Xiang Y
    Protein Cell; 2022 May; 13(5):336-359. PubMed ID: 33417139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia.
    Deng R; Jiang K; Chen F; Miao Y; Lu Y; Su F; Liang J; Qian J; Wang D; Xiang Y; Shen L
    Biomed Pharmacother; 2022 Oct; 154():113606. PubMed ID: 36030589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
    Chen S; Wang Q; Bakker D; Hu X; Zhang L; van der Made I; Tebbens AM; Kovácsházi C; Giricz Z; Brenner GB; Ferdinandy P; Schaart G; Gemmink A; Hesselink MKC; Rivaud MR; Pieper MP; Hollmann MW; Weber NC; Balligand JL; Creemers EE; Coronel R; Zuurbier CJ
    Basic Res Cardiol; 2024 Oct; 119(5):751-772. PubMed ID: 39046464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts.
    Mizuno M; Kuno A; Yano T; Miki T; Oshima H; Sato T; Nakata K; Kimura Y; Tanno M; Miura T
    Physiol Rep; 2018 Jun; 6(12):e13741. PubMed ID: 29932506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin.
    Xu Y; Jiang K; Chen F; Qian J; Wang D; Wu Y; Zhou C; Yu Y; Chen K; Hwa J; Yang B; Wang H; Xiang Y
    Basic Res Cardiol; 2022 Sep; 117(1):47. PubMed ID: 36171393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of empagliflozin and sotagliflozin on a zebrafish model of diabetic heart failure with reduced ejection fraction.
    Kim I; Cho HJ; Lim S; Seok SH; Lee HY
    Exp Mol Med; 2023 Jun; 55(6):1174-1181. PubMed ID: 37258583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.
    Silva Dos Santos D; Turaça LT; Coutinho KCDS; Barbosa RAQ; Polidoro JZ; Kasai-Brunswick TH; Campos de Carvalho AC; Girardi ACC
    Sci Rep; 2023 May; 13(1):8689. PubMed ID: 37248416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT2 inhibitors protect cardiomyocytes from myocardial infarction: a direct mechanism?
    Zhang J; Zhang F; Ge J
    Future Cardiol; 2022 Nov; 18(11):867-882. PubMed ID: 36111579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy.
    Ren C; Sun K; Zhang Y; Hu Y; Hu B; Zhao J; He Z; Ding R; Wang W; Liang C
    Front Pharmacol; 2021; 12():664181. PubMed ID: 33995090
    [No Abstract]   [Full Text] [Related]  

  • 14. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy.
    Madonna R; Moscato S; Cufaro MC; Pieragostino D; Mattii L; Del Boccio P; Ghelardoni S; Zucchi R; De Caterina R
    Cardiovasc Res; 2023 May; 119(5):1175-1189. PubMed ID: 36627733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice.
    Liu Y; Wu M; Xu J; Xu B; Kang L
    Eur J Pharm Sci; 2021 Jun; 161():105788. PubMed ID: 33684486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
    Oshima H; Miki T; Kuno A; Mizuno M; Sato T; Tanno M; Yano T; Nakata K; Kimura Y; Abe K; Ohwada W; Miura T
    J Pharmacol Exp Ther; 2019 Mar; 368(3):524-534. PubMed ID: 30552292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a.
    Goerg J; Sommerfeld M; Greiner B; Lauer D; Seckin Y; Kulikov A; Ivkin D; Kintscher U; Okovityi S; Kaschina E
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34063987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis.
    Sayour AA; Celeng C; Oláh A; Ruppert M; Merkely B; Radovits T
    Diabetologia; 2021 Apr; 64(4):737-748. PubMed ID: 33483761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
    Nikolaou PE; Mylonas N; Makridakis M; Makrecka-Kuka M; Iliou A; Zerikiotis S; Efentakis P; Kampoukos S; Kostomitsopoulos N; Vilskersts R; Ikonomidis I; Lambadiari V; Zuurbier CJ; Latosinska A; Vlahou A; Dimitriadis G; Iliodromitis EK; Andreadou I
    Basic Res Cardiol; 2022 May; 117(1):27. PubMed ID: 35581445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.